Gastric bypass can result in metabolic changes that cause excess insulin production, says Mary-Elizabeth Patti, M.D., F.A.C.P., Director of the Hypoglycemia Clinic at Joslin Diabetes Center. “People secrete more insulin than they should after eating. Glucose levels spike after a meal and then decline too low. This roller coaster pattern of repeated low blood sugars […]
A recent update on diabetic retinopathy by American Diabetes Association (ADA) has considerably improved in terms of diagnosing and treating this complication since the 2002 ‘Position Statement.’ The statement was comprised of natural history of diabetic retinopathy with associated risk factors and different stages categorized by the growth of new blood vessels on the retina […]
The proportion of deaths attributable to diabetes in the US is as high as 12 percent—three times higher than estimates based on death certificates suggest—a new analysis shows.
A study in Diabetes Care showed that patients with poorly controlled type 2 diabetes who received a combination of exenatide and pioglitazone had a threefold lower rate of hypoglycemia, a one-percentage-point greater reduction in A1C and less weight gain than those in the basal-bolus insulin therapy group.
This study objective was to determine the effect on remission of prediabetes with a high protein (HP) versus high carbohydrate (HC) diet, and effects on metabolic parameters, and lean and fat body mass in prediabetic, obese subjects after 6 months of dietary intervention. They recruited women and men ages 20–50 years with a BMI ≥ […]
We’ve been listening to earnings calls and talking with company execs, industry insiders and PR teams to get a sense of what else is on the horizon, compiled in the following report.
A link between moderate aerobic exercise and improving memory loss in people with diabetes has been found in a new study. Researchers from the University of Tsukaba in Japan found four weeks of moderate activity improved memory dysfunction in mouse models of type 2 diabetes.
A new Bluetooth insulin dose tracker, called Insulog, can be fitted onto most existing insulin pens to prevent dose errors in people with type 1 diabetes and insulin-treated type 2 diabetes. The device, created by a Tel Aviv-based startup, is the object of an online crowdfunding campaign recently launched on Indiegogo.
Both products, known as LixiLan and IDegLira during clinical trials, were delayed by 3 months at the U.S. Food and Drug Administration (FDA) following recommendations for approval from FDA panels back in May. And yet the FDA has approved the two new competing combination products containing fixed doses of glucagonlike-peptide 1 (GLP-1) receptor agonists and […]
The US Food and Drug Administration (FDA) has approved the slow release form of Synjardy. Synjardy is a drug used by people with type 2 diabetes in the UK as a twice daily single pill combination therapy to lower blood sugar levels.
More than 29 million people in the U.S., or 9.3 percent of the population, have diabetes, with 1.7 million people ages 20 years or older diagnosed in 2012 alone, according to the Centers for Disease Control and Prevention (CDC).
On World Diabetes Day, a consortium of international medical organizations is highlighting the fact that a quarter of people with diabetes are not discussing eye complications with their healthcare professional, despite a worldwide survey indicating that vision loss is feared twice as much as other common complications of diabetes.
A global study by the International Diabetes Federation (IDF) has found that many patients don’t know they have type 2 diabetes, usually due to lack of early screening. Very few people take adequate treatment, with almost one in two (46 per cent) patients still undiagnosed among the estimated 415 million adults living with diabetes across […]
The type 2 diabetes drug liraglutide could affect heart variability in newly diagnosed people who are overweight and have heart problems, according to new research. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist which helps control blood sugar levels and reduces post-meal hyperglycemia. The drug is marketed as Victoza and Saxenda.
Diabetes Care, the journal of the American Diabetes Association, published a statement after the 2nd Diabetes Surgery Summit (DSS-II) recognizing metabolic (bariatric) surgery as a standard and safe treatment option for some people with type 2 diabetes.
Consuming junk food can cause high blood sugar levels and the same amount of harm to the kidneys as type 2 diabetes, according to a new study published in Experimental Physiology.
In this small study of 30 people with type 2 diabetes, researchers found that eight weeks on a very low calorie diet of around 600 to 700 calories a day, followed by a less radical six-month weight control diet, led to significant improvement in blood glucose levels in 12 people.
The FDA recently released a Drug Safety Communication announcing revisions to metformin’s label to expand use in people with type 2 diabetes and mild to moderate kidney (renal) impairment. Previously, the FDA advised against using metformin (Glucophage, Glumetza, Riomet, and Fortamet) in this group.
People with Type 1 are not immune from obesity, and some turn to bariatric surgery. However, researchers from the Cleveland Clinic found that 25 percent of those with Type 1 who received this surgery suffered from moderate to severe diabetic ketoacidosis (DKA) afterwards.
Earlier this month, at the Endocrine Society’s annual conference in Boston, Danish pharma Novo Nordisk presented three years of data showing that their diabetes drug liraglutide helped obese and prediabetic patients lose weight without undue risk. Which is big, for a drug that’s been flagged for causing cancer.